

09.00 – 10.30

Room 12

**Inflammation, ageing and the environment**

Chair: Prof Gerry Wilson, University of Sheffield, Sheffield

Aim: To highlight influences of ageing and environmental factors on risk of developing inflammatory diseases

Outcome 1: To understand the effects of ageing on the immune and inflammatory settings

Outcome 2: To understand the potential mechanisms by which exercise and diet influence the immune system

09.00

**Age-related changes in the inflammatory burden**

Prof Janet Lord, University of Birmingham, Birmingham

09.30

**The anti-inflammatory effects of exercise: mechanisms and implications for the prevention of common diseases**

Dr Nicolette Bishop, Loughborough University, Loughborough

10.00

**Diet, genes and health: towards effective personalised nutrition advice**

Prof John Mathers, Newcastle University, Newcastle-upon-Tyne

09.00 – 10.30

Hall 1A

**British Rheumatologists in training session: vasculitis - meet the experts**

Chairs: Dr Elena Nikiphorou, University College London, London and Dr Sonia Panchal, University Hospitals of Leicester NHS Trust, Leicester

Aim: To provide trainees with practical teaching and advice on the management of vasculitis

Outcome 1: Delegates will be able to present and discuss difficult vasculitis cases

Outcome 2: Delegates will have a better understanding of clinical presentation of vasculitis

Outcome 3: Delegates will be able to discuss management issues in complex vasculitis with an expert panel

09.00

**Meet the experts: vasculitis (trainee case presentations followed by discussion involving experts and trainees)**

Dr David Jayne, University of Cambridge, Cambridge and Prof Raashid Luqmani, University of Oxford, Oxford

09.00 – 10.30

Hall 1C

**Statistics, damn statistics and rheumatology**

Chair: Prof Nigel Arden, University of Oxford, Oxford

Aim: For rheumatology professionals to enhance their understanding of quantitative methodology including study design, statistical analysis and issues around complex data, such that they may further improve their ability to conduct research and to interpret research studies

Outcome 1: To understand – (a) the basics of study design; (b) why different research designs are important; (c) how design dictates the analytical methods; (d) what are the commonly encountered designs in rheumatology

Outcome 2: To learn about: (a) basic statistical research methods; (b) which tests and techniques accompany different study designs; (c) statistical methods used in rheumatology; (d) common statistical pitfalls and faux pas

Outcome 3: To gain awareness of: (a) more novel approaches to enhance design and analysis (e.g. linkage of health care data); (b) issues relating to handling and interpreting more complex data (e.g. repeated measurements, missing data)

09.00

**An introduction to study design for professionals in rheumatology**

Dr David Culliford, University of Southampton, Southampton

09.25

**An introduction to statistical methods for professionals in rheumatology**

Dr Gemma Wallace, University of Oxford, Oxford

09.50

**An introduction to complex data for professionals in rheumatology**

Dr Kelvin Jordan, Keele University, Keele

10.15

**Session summary and questions**

Interactive  
keypad session

09.00 – 10.30

Room 3B

**Addressing inactivity: health benefits for inflammatory and non-inflammatory patients**

Chair: Dr Jill Halstead, University of Leeds, Leeds and Dr Simon Till, University of Sheffield, Sheffield

- Aim: To provide clinicians and therapists with an overview of the issues surrounding inactivity and sedentary lifestyle and provide practical knowledge of exercise prescription for arthritis patients
- Outcome 1: Delegates will be able to understand the impact of inactivity upon cardio-respiratory fitness and the onset and development of co-morbidities
- Outcome 2: Delegates will have an understanding of motivational interviewing techniques to engender lifestyle change
- Outcome 3: Delegates will have a better understanding of the barriers to physical activity and exercise prescription for arthritis patients

09.00 **Physical activity and sedentary behaviour: health implications for the rheumatology multidisciplinary team**

Prof Stuart Biddle, Loughborough University, Loughborough

09.30 **Understanding behaviour change: the role of motivational interviewing**

Dr Jeff Breckon, Sheffield Hallam University, Sheffield

10.00 **Exercise prescription: a practical guide to prescribing physical activity for patients with arthritis**

Dr Eleanor Tillett, University College London, London

09.00 – 10.30

Room 11B

**Imaging pathogenesis oral abstracts**

Chairs: Prof Philip Conaghan, Chapel Allerton Hospital, Leeds and Dr Pamela Peterson, Newcastle University, Newcastle-upon-Tyne

09.00 **Ultrasound measures of synovitis reflects histological synovial inflammation in early arthritis patients**

Dr Nora Ng, Queen Mary University of London, London

09.15 **Can we replace temporal artery biopsy with cranial ultrasound for the diagnosis of giant cell arteritis? A retrospective cohort study of the diagnostic utility of ultrasound in routine clinical practice**

Dr Adam Croft, University of Birmingham, Birmingham

09.30 **The case is cracked: identification of a new suspect in the initiation of osteoarthritis**

Prof Alan Boyde, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London



09.45 **Cardiac MRI abnormalities are associated with arrhythmogenic events in systemic sclerosis: evidence for the use of the implantable cardiac defibrillator as primary prevention of sudden cardiac death**

Dr Matthew Webber, Royal Free Hospital, London

10.00 **Longitudinal assessment of scleroderma skin by optical coherence tomography: preliminary validation of sensitivity to change over-time**

Dr Giuseppina Abignano, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds



10.15 **Imaging atherosclerotic plaque inflammation in rheumatoid arthritis: methodology and initial findings in a single centre cohort study**

Dr Sarah Skeoch, University of Manchester, Manchester

09.00 – 10.30

Room 3A

**Nurse-led care: setup, issues and opportunities**

Chairs: Ms Jill Firth, Pennine MSK Partnership Ltd, Oldham and Dr Sarah Ryan, University Hospital of North Staffordshire, Stoke-on-Trent

- Aim: To provide an overview of nurse-led care (NLC) setup and how its benefits can be maximised
- Outcome 1: Delegates will have an increased awareness of how NLC service is set up, practical issues, quality assurance and auditing
- Outcome 2: Delegates will have an example of evidence-based NLC service for newly diagnosed patients from Denmark
- Outcome 3: Delegates will have a greater understanding of the evidence and the opportunities for improving NLC in rheumatology

09.00

**Nurse-led care in rheumatology: service setup, practical issues, quality assurance and auditing**

Mrs Patricia Cornell, Poole Hospital NHS Foundation Trust, Poole

09.30

**Nurse-led screening for cardiovascular risk in rheumatoid arthritis and other types of inflammatory arthritis. Experience from Denmark**

Dr Jette Primdahl, King Christian X's Hospital for Rheumatic Diseases, Graasten, Denmark

10.00

**Nurse-led care: is the future orange? Using the evidence to maximise the effects**

Dr Mwidimi Ndosì, Chapel Allerton Hospital, Leeds



09.00 – 10.30

Hall 1B

**Adolescent and young adult special interest group**

Chairs: Dr Flora McErlane, Great North Children's Hospital, Newcastle-upon-Tyne and Dr Alison Jordan, Queen Elizabeth Hospital Birmingham, Birmingham

- Aim: To promote high quality, young person friendly health services, engaging and informing stakeholders across paediatric, adolescent, and adult groups
- Outcome 1: To promote and improve understanding of the You're Welcome criteria: a Department of Health initiative to improve health outcomes in young people
- Outcome 2: To understand the challenges of ensuring continuous, high quality healthcare for adolescents and young adults and explore how young people friendly services have been achieved in different centres across the UK
- Outcome 3: To explore long-term health outcomes in young people with juvenile idiopathic arthritis (JIA), with particular reference to cardiovascular morbidity and mortality

09.00

**Developing young people friendly musculoskeletal services: the Sheffield experience**

Dr Rachel Tattersall, Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield Children's Hospital, Sheffield

09.30

**Integrating research into rheumatology services for young people**

Mrs Helen Hanson, University of Newcastle, Newcastle-upon-Tyne

10.00

**Cardiovascular risk in adults with juvenile idiopathic arthritis**

Dr Elizabeth Coulson, University of Newcastle, Newcastle-upon-Tyne

09.00 – 10.30

Room 4

**Scleroderma special interest group**

Chair: Prof Chris Denton, Royal Free Hospital, London

- Aim: To update on management of renal scleroderma and pulmonary hypertension in scleroderma
- Outcome 1: Understand the best current management of scleroderma renal crisis
- Outcome 2: Review latest developments in screening and treating pulmonary hypertension in scleroderma
- Outcome 3: Consider novel approaches to therapy: new agents and intensive immunosuppression and relevance to renal crisis and pulmonary hypertension

09.00

**Management of scleroderma associated pulmonary hypertension**

Dr David Kiely, Sheffield University, Sheffield

09.30

**Management of scleroderma renal crisis**

Dr Voon Ong, Royal Free Hospital, London

10.00

**Consider novel approaches to therapy: new agents and intensive immunosuppression**

Prof Jacob van Laar, University Medical Centre, Utrecht, the Netherlands

10.40 – 11.10

Hall 1A

Aim:	To provide delegates with the tools to submit a quality abstract submission
Outcome 1:	Delegates will understand the key issues surrounding a quality abstract submission
Outcome 2:	Delegates will be able to critically analyse an abstract submission with a view to improving the quality
Outcome 3:	Delegates will be able to re-formulate an abstract to make a quality submission

10.40

**How to get your abstract published****How to get your abstract published**

Dr David Coady, Sunderland General Hospital, Sunderland

10.30 – 11.30

**Exhibition | Tea and coffee**

Exhibition hall



Please see exhibition floor plan on page 89 for catering points.

10.30 – 11.30

Exhibition hall

**Poster viewing categories**

232–240 Basic science

241–242 Biology of bone cartilage and connective tissue

243 Cell receptor-ligand interaction signalling activation and apoptosis

244 Cytokines and inflammatory mediators

245–262 Education

263–266 Genetics

267–272 Imaging

273–278 Metabolic and crystal arthropathies

279–297 Paediatric and adolescent rheumatology

298–303 Pain

304–320 Scleroderma and related disorders

321–331 Systemic lupus erythematosus and antiphospholipid syndrome

332–343 Vasculitis

Day three of our ever popular poster tours. Small groups are led by experts around carefully selected posters for a Q&A with the poster presenters. Each expert will lead delegates through a group of approximately 10 posters, allowing presenters to share their research in an interactive format.

Sign up for the poster tours at the poster desk in the **exhibition hall**. Tours are limited to 15 participants.

10.30 – 11.30

Exhibition hall



### Adolescent and paediatric rheumatology poster tour

Poster tour leader: Dr Helen Foster, Newcastle University, Newcastle-upon-Tyne

**280 Musculoskeletal anomalies in a national cohort of children and adolescents with trisomy 21**

Dr Charlene Foley, Our Lady's Children's Hospital, Dublin, Ireland

**282 Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years weighing kg**

Dr Hartmut Kupper, AbbVie Deutschland GMBH & Co., Ludwigshafen, Germany

**284 Enthesitis related arthritis and two distinct patterns of disease: clinical characteristics and outcomes in a cohort of 109 patients**

Dr Corinne Fisher, University College London and Great Ormond Street Hospital, London

**289 Assessment of radiographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year results from the tender trial**

Assoc Prof Dr Angelo Ravelli, Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy

**290 Being 'as normal as possible': how young people value the risks and benefits of treatment**

Ms Ruth Hart, Newcastle University, Newcastle-upon-Tyne

**293 Use of non-etanercept biologics in children with juvenile idiopathic arthritis: results from the biologics for children with rheumatic diseases study**

Mrs Lianne Kearsley-Fleet, University of Manchester, Manchester

**295 Paradoxically elevated levels of tumour necrosis factor in patients with juvenile idiopathic arthritis on etanercept**

Dr Corinne Fisher, University College London and Great Ormond Street Hospital, London

**296 The relationship between benign joint hypermobility syndrome and motor difficulties in children**

Mrs Victoria Easton, Norfolk and Norwich University Hospital, Norwich

10.30 – 11.30

Exhibition hall

**Scleroderma poster tour**

Poster tour leader: Dr Marina Anderson, University of Liverpool, Liverpool

**304 Modulating the fibrotic effects of fibrocytes from scleroderma patients**

Dr Sarah Trinder, University College London, London

**305 Anticentromere antibody disease duration and history of surgical debridements predict calcinosis in patients with systemic sclerosis**

Dr Joanne Manning, Salford Royal NHS Foundation Trust, Salford

**306 IL6 trans-signalling mediates M2 macrophage polarisation and fibrotic response in SSC**

Miss Rebecca Alade, University College London, London

**307 Long term survival in systemic sclerosis patients: development of a predictive model**

Dr Svetlana Nihtyanova, University College London, London

**309 Investigating the role of MRTF-A in systemic sclerosis**

Dr Richard Stratton, Royal Free Hospital, London

**311 Multiplex cytokine analysis of dermal interstitial blister fluid in systemic sclerosis defines potential pathogenic pathways and differentiates clinical subsets**

Dr Kristina Clark, University College London, London

**313 Nail-fold capillaroscopy abnormalities in an unselected cohort of patients with Raynaud's phenomenon confirms significant association of antibody positivity and SSC pattern: experience from a single tertiary centre**

Dr Lesley-Anne Bissell, University of Leeds, Leeds

**316 Retrospective review of patients with systemic sclerosis on home parenteral nutrition**

Dr Elizabeth Harrison, University of Manchester, Manchester

**320 The prognosis of scleroderma renal crisis in rna-polymerase iii antibody (ARA) positive compared to ARA negative patients**

Dr Bernadette Lynch, University College London, London

10.30 – 11.30

Exhibition hall

**Vasculitis poster tour**

Poster tour leader: Prof David G. I. Scott, Norfolk and Norwich University Hospital, Norwich

**332 Increased circulating TH17 and NKT cells in takayasu's arteritis**

Dr Durga Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

**333 Long-term efficacy and safety of rituximab in anca associated vasculitis: results from a UK tertiary referral centre**

Dr Fiona Pearce, Queen's Medical Centre, Nottingham

**334 United Kingdom and Ireland vasculitis registry (UKIVAS): cross-sectional data on the first 556 patients**

Dr Jan Sznajd, University of Oxford, Oxford

**335 Factors determining early damage in takayasu's arteritis**

Dr Durga Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

**337 Standardisation of disease assessment in systemic vasculitis: use of a novel web-based software training application**

Dr Jan Sznajd, University of Oxford, Oxford

**338 Hla-dpb alleles and granulomatosis with polyangiitis (Wegener's)**

Dr Richard Watts, University of East Anglia, Norwich

**342 Is plasma viscosity an acceptable substitute for erythrocyte sedimentation rate for the diagnosis of giant cell arteritis?**

Dr Sarah Mackie, University of Leeds, Leeds

**343 Serum vascular endothelial growth factor is selectively upregulated in patients with biopsy-proven giant cell arteritis**

Mr Julien Morlet, Oxford University, Oxford

11.30 – 13.00

Room 12



11.30

**Basic science oral abstracts**

Chairs: Prof Justin Mason, Imperial College London, London and Prof Ian Clark, University of East Anglia, Norwich

**Metabolic profiles of synovial fibroblasts: implications for disease processes in inflammatory arthritis**

Dr Sabrina Kapoor, University of Birmingham, Birmingham

11.45

**Presence of synovial lymphocyte aggregates correlates with a more severe clinical phenotype in patients with early inflammatory arthritis**

Dr Maria Di Cicco, Queen Mary University of London, London

12.00

**Hydroxychloroquine is cardioprotective in neonatal rat cardiomyocytes exposed to simulated myocardial ischaemic/reperfusion injury – an effect mediated through ERK phosphorylation**

Miss Lauren Bourke, University College London, London

12.15

**Proteinase-activated receptor-2 critically influences osteophyte formation in experimental osteoarthritis**

Dr Carmen Huesa, University of the West of Scotland, Paisley

12.30

**SLE susceptibility gene ube2l3 polymorphism controls sensitivity of NF- $\kappa$ B to TNF and CD40 in vivo**

Dr Myles Lewis, King's College London, London



12.45

**Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100a9**

Dr Richard Stratton, Royal Free Hospital, London

11.30 – 13.00

Hall 1A

**British Rheumatologists in training session: clinical teaching on systemic sclerosis**

Chairs: Dr Elena Nikiphorou, University College London, London and Dr Sonia Panchal, University Hospitals of Leicester NHS Trust, Leicester

Aim:

To provide trainees with up-to-date clinical teaching on systemic sclerosis

Outcome 1:

Delegates will have a better understanding of the pathophysiology of systemic sclerosis

Outcome 2:

Delegates will learn the current evidence base for the treatment of systemic sclerosis

Outcome 3:

Delegates will have a better understanding of the management of systemic sclerosis outside of the current evidence base

11.30

**Scleroderma: current clinical challenges and case-based discussion**

Prof Chris Denton, Royal Free Hospital, London and Prof Ariane Herrick, University of Manchester, Manchester



11.30 – 13.00

Hall 1C

**The need and approaches to stratified medicine in inflammatory arthritis**

Chair: Dr Maya Buch, University of Leeds, Leeds

Aim:	To inform the audience in a topical clinical science subject relevant clinical practice
Outcome 1:	Enhance understanding of the need to stratified medicine in inflammatory arthritis
Outcome 2:	Enhance knowledge of potential approaches to stratified medicine
Outcome 3:	Improve patient care through stratified medicine approaches

11.30

**The need for stratified medicine in inflammatory arthritis**

Prof John Isaacs, University of Newcastle, Newcastle-upon-Tyne

11.50

**Genomic approaches to stratified medicine, what have we learnt?**

Prof Anne Barton, University of Manchester, Manchester

12.10

**Metabolic fingerprinting of disease activity and response to therapy**

Dr Stephen Young, University of Birmingham, Birmingham

12.30

**From the disease tissue to the whole patient: the role of pathobiology in patient stratification**

Prof Costantino Pitzalis, Barts and the London School of Medicine and Dentistry, London

11.30 – 13.00

Room 3

**Droitwich lecture and prize session**

Chair: Mr Robert Field, President of British Health Professionals in Rheumatology (BHPR)

The Droitwich lecture marks the highlight of the BHPR programme, incorporating the presentation of the prestigious Droitwich lecturer session and the BHPR award presentations - an opportunity for inspiring allied health professionals to share their work.



11.30

**Remodelling osteoarthritis care: maximising the impact of best evidence**

Prof Krysia Dziedzic, Arthritis Research UK, Professor of Musculoskeletal Therapies, Keele University and NICE fellow

**BHPR**  
 British Health Professionals  
 in Rheumatology

12.15

**British Health Professionals in Rheumatology awards ceremony**

11.30 – 13.00

Hall 1B

**Paediatric and adolescent rheumatology oral abstracts**

Chairs: Dr Jacqui Clinch, University Hospitals Bristol, Bristol and Dr Helen Foster, Newcastle University, Newcastle-upon-Tyne

11.30

**Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children with juvenile idiopathic arthritis (JIA): results from the childhood arthritis prospective study**

Dr Flora McErlane, Great North Children's Hospital, Newcastle-upon-Tyne

11.45

**Early growth of lean, rather than fat mass, predicts bone size, mineralisation and density in childhood: findings from the Southampton women's survey**

Dr Zoe Cole, University of Southampton, Southampton

12.00

**Growth in children and adolescents with juvenile idiopathic arthritis after 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology (BSPAR) etanercept cohort study**

Mrs Lianne Kearsley-Fleet, University of Manchester, Manchester

12.15

**Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis**

Aileen Pangan, AbbVie Inc., Chicago, United States

12.45

**Predictors of pain reporting over time in juvenile idiopathic arthritis using trajectory analysis: results from the childhood arthritis prospective study**

Dr Amir Rashid, University of Manchester, Manchester

11.30 – 13.00

Room 11B

**Lung disease in rheumatoid arthritis special interest group**

Chair: Dr Bridget Griffiths, Freeman Hospital, Newcastle-upon-Tyne

Aim:

To review the data on survival of patients with (a) interstitial lung disease in rheumatoid arthritis (BRILL) (b) bronchiectasis in rheumatoid arthritis (BROAD), and to discuss the developing program for developing drug trials in the management of these conditions

Outcome 1:

To update delegates on the progress made to date within the BRILL and BROAD networks relating to patient outcomes

Outcome 2:

To involve delegates in the assessment of the most relevant clinical questions we now need to address in the management of these disorders

Outcome 3:

To define the structure of drug trials for both interstitial lung disease and bronchiectasis in patients with rheumatoid arthritis

11.30

**What have we learned from our clinical networks on lung disease in rheumatoid arthritis?**

Dr Elizabeth Perry, South West Deanery

12.15

**What clinical questions are rheumatologists now asking about the management of lung disease in rheumatoid arthritis?**

Dr David Hutchinson, Royal Cornwall Hospitals, Truro

12.45

**What studies do we need to do next to answer these issues?**

Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead

11.30 – 13.00

Room 4

**Soft tissue rheumatism and sports medicine special interest group**

Chair: Dr Tim Jones, the Defence Medical Rehabilitation Centre, Headley Court, Epsom

Aim:

To illustrate how rheumatological practice is altered in young, old and female active populations

Outcome 1:

To highlight unusual or important conditions that present to a rheumatology clinic in specific active populations

Outcome 2:

To highlight how important medical conditions may present in atypical ways in active populations

Outcome 3:

To discuss how exercise should be modified in different active populations

11.30

**Unusual cases presenting to a rheumatology clinic from an active young population**

Dr Rhodri Phillip, the Defence Medical Rehabilitation Centre, Headley Court, Epsom

12.00

**Rheumatology for an active ageing population**


Dr Aisling Coy, Salisbury District Hospital, Salisbury

12.30

**Rheumatology in an active female population**

Dr Julia Newton, Oxford University Hospitals, Oxford

11.30 – 13.00		British Society for Rheumatology education special interest group
Room 11A		Chairs: Prof Andrew Hassell, Keele University, Keele and Dr Lesley Kay, Musculoskeletal Services Directorate, Newcastle-upon-Tyne
Aim:	To promote the development of education of rheumatology patients and of health professionals active in the area of rheumatology. To develop networks of rheumatology educators. To develop collaborative research and development projects within the realm of rheumatology education	
Outcome 1:	Using the results of a national study, participants will evaluate the learning needs of rheumatology nurses in the context of treatment counselling	
Outcome 2:	Participants will identify ways of including effective peer supported learning in a curriculum.	
Outcome 3:	Participants will receive an update on the work of Arthritis Research UK (ARUK) in this area, including discussion of the Educators' conference	
11.30	<b>Rheumatology nurses counselling patients re methotrexate: an investigation of educational needs</b> Ms Sandra Robinson, North Tyneside Hospital, North Shields	
11.50	<b>Peer-supported learning in undergraduate medical musculoskeletal modules</b> Dr Kelsey Watt, NHS Lothian	
12.10	<b>The impact of educational resources on adult and paediatric musculoskeletal examination - a UK survey</b> Dr Ken Baker, Newcastle University, Newcastle-upon-Tyne	
12.30	<b>Update on educational activities and opportunities in Arthritis Research UK</b> Dr Inam Haq and Dr Tom Margham, Arthritis Research UK	
12.50	<b>Discussion</b>	

13.00 – 14.15		Exhibition   Lunch
Exhibition hall	 Please see exhibition floor plan on page 89 for catering points.	

13.00 – 14.00	British Health Professionals in Rheumatology members' meeting
<p>You are invited to the</p> <h2>BHPR Members' Meeting</h2> <p>Room 3 Thursday 1 May at 13.00 – 14.00</p> <p> Lunch bags will be provided</p> <p>The first members' meeting follows on from the Droitwich Lecture and prize giving session. The agenda will focus on topical issues such as the national audit, commissioning and regional development.</p> <p>The BHPR regional representatives for the various professions will be there to meet you. Come along and find out more, bring a colleague and get involved.</p> <p>For more information visit our website: <a href="http://www.rheumatology.org.uk/bhpr/meetings">www.rheumatology.org.uk/bhpr/meetings</a></p>	
	

13.00 – 14.15



Hall 1A

**British Rheumatologists in Training Annual General Meeting**

13.00 – 14.15

Hall 1C

**The Standards, Guidelines and Audit Working Group (SAGWG): open forum****Welcome and introduction**

Dr Jo Ledingham, Chair of the Standards, Guidelines and Audit Working Group

**SAGWG update, including call for new guideline topics**

Dr Jo Ledingham, Chair of the Standards, Guidelines and Audit Working Group

**National audits**

Gout: Dr Ed Roddy, Clinical Senior Lecturer in Rheumatology and Honorary Consultant Rheumatologist, Keele University, Keele

HQIP: Catherine Burns, Project Director



14.15 – 15.45

Room 12

**Advances in innate immunity and rheumatology**

Chair: Dr Kim Midwood, University of Oxford, Oxford

Aim:

To provide an update on emerging data that reveal new ways in which innate inflammation mediates joint destruction in rheumatoid arthritis

Outcome 1:

Delegates will gain an understanding of the biology of microRNAs, as well as an appreciation of how these fascinating, multifunctional molecules sustain chronic inflammation in the rheumatoid arthritis symposium

Outcome 2:

Delegates will learn more about a newly identified subset of B cells that exhibit the surprising ability to suppress inflammation, as well as learning how these cells become dysregulated in rheumatoid arthritis

Outcome 3:

Delegates will gain an understanding of the complexities of innate immune sensing and the mechanisms by which receptors designed to detect pathogens and tissue injury drive inflammation in immune diseases

14.15

**The role of microRNAs in the regulation of the immune response in arthritis**

Dr Mariola Kurowska-Stolarska, University of Glasgow, Glasgow

14.45

**Regulatory B cells in health and arthritis**

Dr Mohini Gray, University of Edinburgh, Edinburgh

15.15

**Innate immune sensing: toll like receptors and beyond**

Prof Kathy Triantafilou, Cardiff Institute of Infection &amp; Immunity, Cardiff

14.15 – 15.45

Hall 1A

**British Rheumatologists in Training session: adding value to your CV**

Chair: Dr Elena Nikiphorou, University College London, London and Dr Sonia Panchal, University Hospitals of Leicester NHS Trust, Leicester

Aim:

To inform trainees on new NHS reforms, the impact on rheumatology and ways of adding value to their CV

Outcome 1:

Delegates will have a better understanding of new NHS reforms and their impact on rheumatology, learn about new initiatives e.g. Best Practice Tariffs

Outcome 2:

Delegates will have an opportunity to present their experience from interesting OOPEs and inspire others

Outcome 3:

Delegates will learn from others' experiences and ways of adding value and improving their CV

14.15

**Gaining knowledge and experience of the healthcare environment: outside the curriculum!**

Dr Gavin Clunie, Ipswich Hospital, Ipswich

14.45

**Adding value (how can a District General Hospital add value?)**

Dr Stuart Kyle, North Devon District Hospital, Barnstaple

15.15

**Navigating the new NHS**

Dr Andrew Östör, Addenbrooke's Hospital, Cambridge

14.15 – 15.45

Hall 1B

**Adolescent and young adult rheumatology update**

Chair: Dr Liza McCann, Alder Hey Children's Hospital, Liverpool

- Aim: Update on dermatological manifestations of childhood onset rheumatological conditions and the progression/prognosis in young adulthood
- Outcome 1: Delegates will have enhanced their understanding of adolescent onset spondyloarthropathies and their progress and management into young adult life
- Outcome 2: Delegates will have enhanced their understanding of pathophysiology and management of bone disorders in childhood as they transition into young adult life

14.15

**Dermatological manifestations of childhood and adolescent onset rheumatological diseases; recognition, treatment and prognosis into young adulthood**

Dr Cameron Kennedy, Bristol Children's Hospital, Bristol

14.45

**Adolescent onset spondyloarthropathies and enthesitis related arthritis: current understanding of pathophysiology, management and prognosis as patients enter early adulthood**

Dr Rachel Tattersall, Sheffield Teaching Hospitals and Sheffield Children's Hospital, Sheffield

15.15

**Childhood onset osteoporosis: pathophysiology and management as they enter adolescent and young adult life**

Dr Paul Arundel, Sheffield Children's Hospital, Sheffield

14.15 – 15.45

Room 3

**Innovative models of care**

Chair: Dr Melanie Holden, Keele University, Keele and Dr Mwidimi Ndosi, Chapel Allerton Hospital, Leeds

- Aim: To provide clinicians with an overview of innovative models of care, which can improve clinical management
- Outcome 1: Delegates will have a better understanding of potential different, innovative models of care
- Outcome 2: Delegates will be aware of how they could apply the innovative models of care to the clinical management of their own patients
- Outcome 3: Delegates will have a better understanding of the advantages and disadvantages of these innovative models of care

14.15

**PhysioDirect telephone assessment and treatment services: results of a randomised controlled trial**

Prof Chris Salisbury, University of Bristol, Bristol

14.45

**Patient access to online electronic medical records: advantages, disadvantages and preconditions according to care providers**

Dr Erik Taal, University of Twente, Enschede, the Netherlands

15.15

**Print away my arthritis foot pain: next generation 3D printed orthotics**

Prof Jim Woodburn, Glasgow Caledonian University, Glasgow

## 14.15 – 15.45

## Room 4

## Connective tissue disease (CTD) oral abstracts

Chairs: Dr Hector Chinoy, University of Manchester, Manchester and Dr Benjamin Rhodes, University Hospitals Birmingham NHS Foundation Trust, Birmingham

- 14.15 **Prevalence of autoantibodies to HMGCR in myositis patients**  
Dr Zoe Betteridge, University of Bath, Bath
- 14.30 **Microarray transcriptional profiling of limited cutaneous systemic sclerosis identifies a vascular gene expression signature**  
Dr Emma Derrett-Smith, University College London, London
- 14.45 **Autoantibody in juvenile dermatomyositis reflects disease activity: results of a pilot study**  
Dr Sarah Tansley, Royal National Hospital of Rheumatic Diseases, Bath
- 15.00 **Long-term outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine in pregnancy**  
Dr Mary Gayed, University of Birmingham, Birmingham
- 15.15 **The cellular effects of anti-factor XA antibodies isolated from patients with antiphospholipid syndrome are inhibited by factor XA inhibitors, hydroxychloroquine and fluvastatin**  
Dr Bahar Artim-Esen, Istanbul University, Istanbul, Turkey
- 15.30 **Extra-corporeal membrane oxygenation and diffuse alveolar haemorrhage in systemic vasculitides: a single centre case series and analysis of the the Extracorporeal Life Support Organization (ELSO) database database**  
Dr Chai-Yiing Ling, Guy's & St Thomas' Hospital, London

## 14.15 – 15.45

## Room 11C

## MS health of the ethnic minority special interest group

Chairs: Dr Ash Samanta and Dr Arumugam Moorthy, University Hospitals of Leicester NHS Trust, Leicester


- Aim: To provide an overview of the issues relating to ethnicity and rheumatic diseases
- Outcome 1: Delegates will have a better understanding of the relevance of ethnic variations in rheumatic diseases
- Outcome 2: Delegates will be able to improve their management of ethnic minority patients with inflammatory arthritis
- Outcome 3: Delegates will be able to identify ways of enhancing patient education and empowerment for ethnic groups
- 14.15 **Epidemiology of rheumatic diseases in different ethnic groups**  
Prof Deborah Symmonds, University of Manchester, Manchester
- 14.45 **Challenges in managing ethnic minority patients with rheumatic diseases**  
Dr Arumugam Moorthy, University Hospitals of Leicester NHS Trust, Leicester
- 15.15 **Commissioning musculoskeletal service: influence of ethnicity**  
Prof Peter Kay, Wrightington Hospital, Wigan



14.15 – 15.45		<b>Foot and ankle special interest group</b>	
<b>Room 11B</b>		Chair: Dr Catherine Bowen, University of Southampton, Southampton	
Aim:	To discuss the clinical importance of the advent of biological therapies to manage rheumatoid arthritis relative to foot pathology and the implementation of new approaches to foot healthcare/management		
Outcome 1:	Delegates will review rheumatoid arthritis foot pathologies and consider the current evidence that investigates the primary aetiology as mechanical, inflammatory or both		
Outcome 2:	Delegates will consider whether biologic therapies have a significant impact on the management of rheumatoid arthritis foot pathology		
Outcome 3:	Delegates will discuss investigation of the role of specialist podiatry foot-care alongside regular rheumatology care and biologic therapy		
14.15	<b>Introduction to the use of, and monitoring of, biologic therapies for rheumatoid arthritis and consideration to the inclusion of foot pathologies</b>		
	Dr Christopher Edwards, University Hospitals Southampton, Southampton		
14.35	<b>Foot disease in the post-biologic era: is it mechanical or inflammatory?'</b>		
	Dr Heidi Siddle, University of Leeds, Leeds		
14.55	<b>FeeTURA4: longitudinal evaluation of biologic therapies on rheumatoid arthritis foot pathology</b>		
	Dr Lindsey Cherry, University of Southampton, Southampton		
15.15	<b>The 'Rheumafollow' multicentre parallel trial of podiatry care in rheumatoid arthritis: clinical study group (CSG) proposal update</b>		
	Dr Gordon Hendry, Glasgow Caledonian University, Glasgow		
15.35	<b>Discussion</b>		

14.15 – 15.45		<b>British Health Professionals in Rheumatology osteoporosis special interest group</b>	
<b>Room 11A</b>		Chair: Ms Rachel Lewis, Cardiff University, Cardiff	
Aim:	To increase knowledge of management of acute vertebral fracture and common Fracture Liaison Services (FLS) questions		
Outcome 1:	Increased confidence in answering complex Fracture Liaison Services questions from patients		
Outcome 2:	To have a multi-disciplinary/holistic awareness for acute vertebral fracture management		
Outcome 3:	To have participated in peer discussion on case studies		
14.15	<b>Common and complex fracture liaison questions and discussion</b>		
	Ms Cathy Churchman, United Bristol Healthcare Trust, Bristol		
14.45	<b>Acute vertebral fracture management the multidisciplinary team whole story</b>		
	Dr Rachel Lewis, North Bristol NHS Trust, Bristol		



15.45 – 16.00		<b>Tea and coffee</b>	
<b>Upper level foyer</b>		 This refreshment break is for those attending sessions scheduled at the end of the conference (16.00 – 17.30)	

16.00 – 17.00

Room 11A

**British Society for Rheumatology NICE-accredited clinical guidelines****Welcome and Introduction**

Dr Jo Ledingham, Chair of the Standards and Guidelines Working Group

**Guideline updates:****De-modifying anti-rheumatic drug (DMARD) use in rheumatoid arthritis**

Dr Tom Kennedy, Royal Liverpool University Hospital, Liverpool

**Management of polymyalgia rheumatica**

Prof Bhaskar Dasgupta, Southend University Hospital, Southend-on-Sea

**Gout management**

Prof George Nuki, University of Edinburgh, Edinburgh

**Question and answer session**

16.00 – 17.30

Hall 1C

**Rheumatoid arthritis outcomes special interest group**

Chair: Dr Adam Young, City Hospital, St Albans

Aim:

Recent developments and reviews affecting the management of rheumatoid arthritis and its outcomes

Outcome 1:

Defining and developing a minimum core dataset for clinical trials and observational studies of rheumatoid arthritis

Outcome 2:

The importance, measurement and management of comorbidities in the management of rheumatoid arthritis

Outcome 3:

The level of knowledge and understanding of health economics that rheumatologist should be aware

16.00

**Development of a minimum core dataset in rheumatoid arthritis: a multidisciplinary exercise**

Dr Elena Nikiphorou, University College London, London

16.20

**How important is comorbidity in rheumatoid arthritis? Results from an Arthritis Research UK Clinical Study Group Work**

Dr Peter Dawes, Haywood Hospital, Stoke-on-Trent

16.40

**Should we be assessing fatigue in rheumatoid arthritis and if so, how?**

Prof Sarah Hewlett, University of the West of England, Bristol

17.00

**What rheumatologists need to know about health economics in management of rheumatoid arthritis**

Prof Alan Willoo, the School of Health and Related Research (SchARR), Sheffield and Dr Chris Deighton, President of the British Society for Rheumatology

17.20

**Discussion**

16.00 – 17.30

Room 12

**Heritable disorders of connective tissue disease special interest group**

Chair: Prof Rodney Grahame, University College London, London

16.00

**Comprehensive care for hypermobility: filling in the gaps  
Experts, networks and commissioning**

- A national perspective  
Dr Alan Hakim, London
- Local perspectives  
Bill Ferrell, Glasgow

16.30

**Allied health professionals education and training**

Jane Simmonds, University of Hertfordshire, Hertfordshire

16.50

**Patient information and public awareness**

Donna Wicks, Hypermobility Syndromes Association (HMSA)

17.05

**Discussion**





## British Society for Rheumatology NICE accredited clinical guidelines

The British Society for Rheumatology guidelines gained NICE accreditation in February 2013, after a rigorous assessment of our guideline development process. BSR guidelines are permitted to include the NICE accreditation mark as a sign of quality assurance for the next five years.



The National Institute for Health and Care Excellence (NICE) is an independent organisation which provides authoritative and evidence-based guidance on the most effective ways to prevent, diagnose and treat disease and ill health.

Its accreditation programme helps health and social care professionals identify the most robustly produced guidance available, enabling them to deliver high quality care.

### BSR guidelines update

#### New guidelines - recently published:

- Vasculitis management

Expected shortly:

- Tocilizumab use in rheumatoid arthritis

Please join us at **Rheumatology 2014** for a session on updates to our guidelines on **Thursday 1 May at 16.00**. The session will be chaired by Dr Jo Ledingham, Chair of the Standards and Guidelines Working Group, and provide updates on the following:

- DMARD use in rheumatoid arthritis:  
*Dr Tom Kennedy*
- Management of polymyalgia rheumatica:  
*Prof Bhaskar Dasgupta*
- Gout management:  
*Prof George Nuki*

**Do you have any suggestions for new evidence-based clinical practice guideline topics? Please let us know – we'd love to hear from you.**

For more information, please see  
[www.rheumatology.org.uk/guidelines](http://www.rheumatology.org.uk/guidelines)

16.00 – 17.30

Room 11C

**British Health Professionals in Rheumatology rheumatoid arthritis special interest group**

Chair: Ms Janet Cushnaghan, Hampshire Hospitals NHS Foundation Trust, Tadley

- Aim: Delegates will participate in a session about various aspects of interest in rheumatoid arthritis  
 Outcome 1: Delegates will increase their knowledge of a treat to target approach in rheumatoid arthritis  
 Outcome 2: Delegates will gain an insight into patient preferences for route of administration of biologics  
 Outcome 3: Delegates will understand the issues around adherence with medication and how to improve

16.00

**Experiences of healthcare provision for foot ulceration in rheumatoid arthritis**

Dr Jill Firth, University of Leeds, Leeds

16.40

**Medication adherence in rheumatoid arthritis**

Dr Kanta Kumar, University of Birmingham, Birmingham



16.00 – 17.30

Room 11B

**Vasculitis special interest group**Chairs: Dr David Carruthers, Sandwell & West Birmingham Hospitals, Birmingham;  
 Prof Raashid Luqmani, University of Oxford, Oxford and Dr Chetan Mukhtyar, Norfolk and  
 Norwich University Hospital, Norwich

- Aim: To provide an update on current progress in epidemiology, trials, registries and clinical practice in the management of systemic vasculitis  
 Outcome 1: To understand how to measure disease activity and damage in systemic vasculitis using current clinical tools, to facilitate use of immunosuppressive therapies including biologics  
 Outcome 2: To understand the role of different therapies in the treatment of vasculitis in adults and children  
 Outcome 3: To understand the long term outcome, including mortality risk, co-morbidity, drug toxicity relapse and end stage organ disease in different forms of systemic vasculitis demiology and disease burden in systemic vasculitis

16.00

**Epidemiology and disease burden in systemic vasculitis**

Dr Richard Watts, Ipswich Hospital, Ipswich

16.20

**Practical evaluation of systemic vasculitis: using the Birmingham Vasculitis Activity Score (BVAS) and Vasculitis Damage Index (VDI) in everyday management and in clinical studies**

Prof Raashid Luqmani, University of Oxford, Oxford

16.50

**Emerging studies in paediatric vasculitis**

Dr Marinka Twilt, University of Birmingham, Birmingham

17.10

**Getting involved in current studies and registries: how can I help?**

Dr Neil Basu, University of Aberdeen, Aberdeen

16.00 – 17.30

**Musculoskeletal ultrasound special interest group**

Hall 1B

Chair: Dr Ash Samanta, University Hospitals of Leicester NHS Trust, Leicester

- Aim:** To provide rheumatologists/Allied Health Professionals with an outline of changes in training resources available, how the British Society for Rheumatology's training programmes are changing to take advantage of them, and offering advice how to tailor training to suit individual needs
- Outcome 1:** Delegates will gain insight into the practical role ultrasound can have in helping understand anatomy and assessment
- Outcome 2:** Delegates will be aware of the different ultrasound training resources and programmes that are available
- Outcome 3:** Delegates will have a better understanding of how to access ultrasound training that is appropriate for their need

16.00

**Basic and functional anatomy**

Dr Zunaid Karim, Pinderfields Hospital, Wakefield

16.25

**Ultrasound training; what's out there, and what's changing?**

Dr Cristina Estrach, Aintree University Hospital, Liverpool

16.50

**Ultrasound training; what is best for you?**

Dr Alison Hall, Keele University, Keele

17.15

**Panel discussion, interactive with questions and answers**

# HEBERDEN LIBRARY CATALOGUE

## now available online

The Heberden Library is an important collection of medico-historical books on rheumatism, gout and other allied conditions. It is maintained by the Royal College of Physicians on behalf of the British Society for Rheumatology and contains over 1,500 books, pamphlets and journals dating from 1534 to the present day.

The Heberden Library catalogue is now available to search online, and includes all the currently-catalogued books housed at Bride House and at the Royal College of Physicians.

Visit the British Society for Rheumatology's website at [www.rheumatology.org.uk](http://www.rheumatology.org.uk) for further information and to access the online catalogue.

Woodcut illustration of gout sufferers from Eyn verantwortung Podagrae vor dem Richter [Gout answers before the judge], published Mainz, 1537.



